Ambivalency at the bedside: intraperitioneal chemotherapy

被引：2

作者：

Rodriguez, Anne O'Meara ^{[1
]}

机构：

[1] Univ Calif Davis, Dept Obstet & Gynecol, Sacramento, CA 95817 USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2007年 / 19卷 / 01期

关键词：

D O I：

10.1097/GCO.0b013e328011cb5e

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

引用

页码：1 / 2

页数：2

共 10 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[2] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[3] Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Noud-Ovest [J].

Gadducci, A ;

Carnino, F ;

Chiara, S ;

Brunetti, I ;

Tanganelli, L ;

Romanini, A ;

Bruzzone, M ;

Conte, PF .

GYNECOLOGIC ONCOLOGY, 2000, 76 (02) :157-162

[4] Intraperitoneal chemotherapy for ovarian cancer [J].

Hamilton, Chad A. ;

Berek, Jonathan S. .

CURRENT OPINION IN ONCOLOGY, 2006, 18 (05) :507-515

[5] A COMPARISON OF INTRAVENOUS VERSUS INTRAPERITONEAL CHEMOTHERAPY FOR THE INITIAL TREATMENT OF OVARIAN-CANCER [J].

KIRMANI, S ;

BRALY, PS ;

MCCLAY, EF ;

SALTZSTEIN, SL ;

PLAXE, SC ;

KIM, S ;

CATES, C ;

HOWELL, SB .

GYNECOLOGIC ONCOLOGY, 1994, 54 (03) :338-344

[6] Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group [J].

Markman, M ;

Bundy, BN ;

Alberts, DS ;

Fowler, JM ;

Clark-Pearson, DL ;

Carson, LF ;

Wadler, S ;

Sickel, J .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :1001-1007

[7] Challenges for chemotherapy in ovarian cancer [J].

Ozols, R. F. .

ANNALS OF ONCOLOGY, 2006, 17 :V181-V187

[8] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J].

Ozols, RF ;

Bundy, BN ;

Greer, BE ;

Fowler, JM ;

Clarke-Pearson, D ;

Burger, RA ;

Mannel, RS ;

DeGeest, K ;

Hartenbach, EM ;

Baergen, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3194-3200

[9] A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer [J].

Polyzos, A ;

Tsavaris, N ;

Kosmas, C ;

Giannikos, L ;

Katsikas, M ;

Kalahanis, N ;

Karatzas, G ;

Christodoulou, K ;

Giannakopoulos, K ;

Stamatiadis, D ;

Katsilambros, N .

ONCOLOGY, 1999, 56 (04) :291-296

[10]

YEN MS, 2001, INT J GYNECOL OBSTET, V19, P1001

← 1 →